Skip to main content

A Mount Sinai Team of Urologic Researchers Advances a Unique Model of Bladder Cancer Resistance


An inactivated form of tuberculosis bacterium known as Bacillus Calmette-Guerin (BCG) has been the only first-line therapy for urologists treating non-muscle invasive bladder cancer. A team of clinician-researchers from Mount Sinai’s Department of Urology is searching for novel therapeutic agents, buoyed by three new grants.

Learn More